This clinical trial is focused on studying the treatment of hospital-acquired pneumonia, a type of lung infection that patients can get while staying in the hospital. The study is investigating the use of a medication called dexamethasone phosphate, which is given as a solution through an injection or infusion into the veins. This medication is being tested to see if it can help treat severe cases of hospital-acquired pneumonia in patients who have a strong inflammatory response, which means their bodies are reacting with a lot of inflammation.
The purpose of the study is to find out how effective dexamethasone phosphate is when used alongside the usual care that patients receive, compared to a placebo, which is a substance with no active medication. The study will involve patients receiving either the medication or the placebo, and their progress will be monitored over a period of time. The treatment with the medication or placebo will last for up to five days, and the patients’ health will be checked regularly to see how they are responding to the treatment.
Throughout the study, researchers will look at various outcomes, such as whether the pneumonia is cured and the overall survival of the patients after 28 days. They will also monitor for any side effects or complications that might occur during the treatment period. The study aims to provide valuable information on whether dexamethasone phosphate can be a beneficial addition to the standard care for patients with severe hospital-acquired pneumonia.
Belgium 
France 
Greece 
Spain 
